Global Market for PCR in Point-of-Care Diagnostics Expected to Reach $2.1 Billion by 2029
Dublin, June 05, 2024 – A recent report titled “Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics 2024-2029” has projected the global market for PCR in point-of-care diagnostics to grow from $1.6 billion in 2024 to $2.1 billion by the end of 2029. This represents a compound annual growth rate (CAGR) of 5.9% from 2024 to 2029.
The report provides a detailed overview of PCR for POC diagnostics, including a competitive landscape and profiles of key market players. It analyzes trends, drivers, limitations, challenges, and opportunities in the market. The study also discusses historical, current, and potential market size, enabling market players to make informed decisions.
Market segmentation is based on product type, analyte, and application. The report offers country-level analysis to better understand the major segments. Key topics covered include market trends, revenue data, market size, competitor analysis, and emerging opportunities in PCR technology.
Leading market participants in the PCR for POC diagnostics market include Abbott, Danaher (Cepheid), Roche, Thermo-Fisher Scientific, and QIAGEN. The report also includes insights on emerging technologies, regulatory frameworks, and sustainability in the market.
For more information about this report, visit the source.
—
**Company Profiles**
– Abbott
– Credo Diagnostics Biomedical Pte. Ltd.
– Danaher Corp.
– F. Hoffmann-La Roche Ltd.
– Qiagen
– Quantumdx Group Ltd.
– Thermo Fisher Scientific Inc.
– Visby Medical Inc.
**About ResearchAndMarkets.com**
ResearchAndMarkets.com is a leading source for international market research reports and data, providing insights on global and regional markets, key industries, top companies, new products, and market trends.
